Results 131 to 140 of about 161,532 (251)
DNA origami-based virus-like particles: a new class of HIV vaccine candidates with superior immunogenic properties. [PDF]
Muecksch F, Hamdan J, Fackler OT.
europepmc +1 more source
Basic research on the PEDV infection cycle and virus–host interactions advances the development of anti‐PEDV drugs and disease‐resistant breeding and helps strengthen disease prevention and control while reducing economic losses in the swine industry.
Heyong Wu +8 more
wiley +1 more source
Protective Immunity Induced by DNA Vaccines Encoding TgGRA47 and TgGRA72 Against <i>Toxoplasma gondii</i> Infection in BALB/c Mice. [PDF]
Zhou Z, Mu J, Sun J, Chen J, Zhou C.
europepmc +1 more source
Objective To identify autoantibodies in presymptomatic individuals that associate with the onset of rheumatoid arthritis (RA) and to distinguish early RA from osteoarthritis (OA), particularly in individuals lacking classic RA serologic markers. Methods We analyzed serum and plasma from three cohorts: presymptomatic individuals who later developed RA ...
Outi Sareila +12 more
wiley +1 more source
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel +18 more
wiley +1 more source
From legacy to innovation: A comprehensive review of vaccine platforms against viral infections. [PDF]
Farsiu N +8 more
europepmc +1 more source
ABSTRACT Neisseria gonorrhoeae poses an urgent public health challenge due to rapidly increasing antimicrobial resistance and the absence of an effective vaccine. Targeting conserved bacterial pathways involved in essential physiological processes may provide new opportunities for vaccine antigen discovery.
Sinethemba H. Yakobi +1 more
wiley +1 more source
Vaccines as treatment for melanoma: an update review. [PDF]
Zhang J, Cao Q, Cen Y, Zhang L, Chen J.
europepmc +1 more source
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva +8 more
wiley +1 more source

